The Bivalent Bromodomain Inhibitor MT-1 Inhibits Prostate Cancer Growth
Bromodomains (BD) are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation of several genes including protooncogene cellular myelocytomatosis (c-Myc). c-Myc is difficult to target directly by agents due to its disordered alpha helical protein stru...
Main Authors: | Sanjeev Shukla, Carlos Riveros, Mohammed Al-Toubat, Jonathan Chardon-Robles, Teruko Osumi, Samuel Serrano, Adam M. Kase, Joachim L. Petit, Nathalie Meurice, Justyna Gleba, John A. Copland, Jay Chauhan, Steven Fletcher, K. C. Balaji |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/15/3851 |
Similar Items
-
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
by: Andrew R Conery, et al.
Published: (2016-01-01) -
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
by: Weiping Li, et al.
Published: (2019-07-01) -
Unveiling the folding mechanism of the Bromodomains
by: Maria Petrosino, et al.
Published: (2017-09-01) -
Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
by: Martin V. Nguyen, et al.
Published: (2020-02-01) -
Long Noncoding RNA <i>PVT1</i> Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression
by: Hiroshi Handa, et al.
Published: (2020-09-01)